Disclosed are bioprinted, three-dimensional, biological skin tissues comprising: a dermal layer comprising dermal fibroblasts; and an epidermal layer comprising keratinocytes, the epidermal layer in contact with the dermal layer to form the three-dimensional, engineered, biological skin tissue. Also disclosed are arrays of engineered skin tissues and methods of making engineered skin tissues.

The invention relates to the use of matrix cells for obtaining a micro hair follicle and to the use thereof for evaluating the effect of cosmetic, pharmaceutical or dermatological products and also for the prophylactic or therapeutic treatment of a state of reduced pilosity.

Methods are disclosed herein for producing human hepatocytes from human induced pluripotent stem cells. Also provided are transgenic rats for the expansion of human hepatocytes, such as those produced using the methods disclosed herein.

A method for promoting replication of infectious bovine rhinotracheitis viruses using cold atmospheric plasma, including: irradiating a medium for Madin-Darby bovine kidney cells with a cold atmospheric plasma generator; adding the irradiated medium to the Madin-Darby bovine kidney cells; and adding infectious bovine rhinotracheitis viruses for incubation. The time required for treatment is 2 min allowing for a simple and rapid operation. The plasma is used for the indirect treatment of cells with a uniform process and a controllable intensity. The replication of the infectious bovine rhinotracheitis viruses in the Madin-Darby bovine kidney cells is significantly promoted by co-incubation in the treated DMEM for 1 hour, so that the high levels of infectious bovine rhinotracheitis viruses obtained can be used for vaccine production after inactivation, improving the vaccine production efficiency.

A composition includes porous silica particles to carry a cell fate modulating factor therein. A method for modulating cell fate includes treating various cells with the composition. The cell fate modulating factor is delivered to a stable target receptor, toxicity to subject cells for delivery may be reduced, a fate of the subject cells can be controlled through sustained release of at least 99 wt. % of the cell fate modulating factor.

It is an object of the present invention to provide a new compound capable of efficiently inducing differentiation from pluripotent stem cells into insulin-producing cells. The object of the present invention is achieved by a compound represented by formula (I): ##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, n and A have the same meanings as defined in the description, respectively, or a salt thereof.

A method of obtaining 3D cell structures including differentiated human hepatic cells. The method includes: a first step of culturing stem cell-derived or immortalized human hepatic progenitors in a non-adherent culture vessel, preferably a low or ultra-low attachment culture vessel; a second step of transferring the stem cell-derived or immortalized human hepatic progenitors to a culture medium including methacrylated gelatin (GelMa), thereby embedding the stem cell-derived or immortalized human hepatic progenitors in a GelMa matrix; and a third step of covering the GelMa matrix with culture medium and culturing the stem cell-derived or immortalized human hepatic progenitors embedded in the GelMa matrix, thereby obtaining 3D cell structures including differentiated human hepatic cells. Also, methods for engineering an artificial liver model or an artificial liver organ, and for assessing in vitro the metabolism, toxicity and/or therapeutic effects of a compound.

Method for manufacturing a tridimensional blood vessel model using stereolithography and optionally cell culture. Applications include surgery training, research on pathology such as SCDs and in vitro drug testing e.g. for antiplatelets. Existing models are not compatible with cell culture and cannot withstand high pressure, as opposed to the present invention. Stereolithography allows modelling of complex vessels such as carotid siphons as opposed to other existing methods.

Compositions and methods for generating insulin-producing beta cells from pluripotent stem cells are provided. The compositions and methods of the present invention involve stepwise differentiation while the differentiating cells are cultured on a lung tissue-derived acellular scaffold.

A method for arterial endothelial-enhanced functional T cell generation is provided. In the method, arterial endothelial cells enhance functional T cell generation by promoting the generation of hematopoietic progenitor cells with T-lineage bias. The first stage of T cell differentiation from human pluripotent stem cells (hPSCs) is optimized, and it is found that hPSC-derived autologous arterial endothelial cells increase the T cell potential of hematopoietic progenitor cells. Moreover, the T cells generated by arterial endothelial cell priming share similar function to that of human peripheral blood T cells. hPSC-derived CD19-CAR-T cells have been verified to have tumor-killing effects both in vivo and in vitro. The established hPSC-T differentiation system would provide a valuable resource for chimeric antigen receptor T cell (CAR-T) therapy.